JSPR — Jasper Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1788028 ·
Last close
$0.91
Market Cap
$25.55M
52W High
$1.45
52W Low
$0.62
ADV30
301,993
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -10,952,000 | -1,174,000 | 21,184,000 | 14,144,000 | 17,784,000 |
| Dec 2025 | 0 | — | -15,839,000 | -9,101,000 | 35,779,000 | 28,692,000 | 31,628,000 |
| Sep 2025 | 0 | — | -19,166,000 | -18,736,000 | 57,469,000 | 50,899,000 | 45,898,000 |
| Jun 2025 | 0 | — | -27,076,000 | -26,723,000 | 46,466,000 | 39,510,000 | 22,965,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-77,161,000
Investing CF
$5,000
Financing CF
$34,211,000
CapEx
$-370,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.60
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-316,670,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-83,883,000
Pretax Income TTM
$-75,801,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -83,883,000 | -75,801,000 | 35,779,000 | 31,628,000 | — | -77,161,000 |
| Dec 2024 | 0 | -76,239,000 | -71,269,000 | 79,899,000 | 18,225,000 | — | -62,602,000 |
| Dec 2023 | 0 | -68,861,000 | -64,465,000 | 94,892,000 | 16,452,000 | — | -52,067,000 |
| Dec 2022 | 0 | -51,196,000 | -37,685,000 | 48,361,000 | 12,372,000 | — | -45,858,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.85
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PLUR | Pluri Inc. | $24.92M | $2.31 | — |
| DYAI | DYADIC INTERNATIONAL INC | $27.51M | $0.75 | — |
| QNCX | Quince Therapeutics, Inc. | $23.47M | $1.20 | — |
| SNTI | Senti Biosciences, Inc. | $30.90M | $0.99 | — |
| ALGS | Aligos Therapeutics, Inc. | $30.93M | $5.74 | — |
News headlines (Yahoo Finance, 1h cache)
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-14 20:05 · Yahoo
Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7
2026-04-07 14:29 · Yahoo
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
2026-03-30 20:30 · Yahoo
Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab
2026-03-29 20:50 · Yahoo
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
2026-02-24 21:30 · Yahoo
Jasper Therapeutics reports updated data from briquilimab studies
2026-01-09 12:15 · Yahoo
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
2026-01-08 12:00 · Yahoo
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
2026-01-07 21:30 · Yahoo
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
2025-12-02 12:00 · Yahoo
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation
2025-12-01 21:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.